Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
View original at finance.yahoo.comMereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Mereo BioPharma Group plc Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Existing cash and cash equivalents will enable funding of operations into mid-2027
60% confidenceThere are no FDA or EMA therapies approved specifically for osteogenesis imperfecta
60% confidenceData from setrusumab studies may provide basis for engagement with regulatory agencies despite missing primary endpoints
60% confidenceAdditional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab in osteogenesis imperfecta are ongoing
60% confidenceSingle Phase 3 trial enrolling approximately 220 AATD-LD patients will support regulatory submissions in both U.S. and Europe
60% confidencePartnering discussions around alvelestat in AATD-LD are continuing to advance on multiple fronts
60% confidenceRevised financial runway into mid-2027 enables potential delivery of several key milestones during 2026
60% confidenceSetrusumab demonstrated statistically significant improvements in bone mineral density and compelling reductions in vertebral fractures
60% confidencePhase 3 Orbit and Cosmic studies did not achieve statistical significance on primary endpoints of fracture reduction
60% confidenceāshibio plans to initiate a Phase 2 trial of vantictumab in osteopetrosis in the second half of 2026
60% confidence